Lidorestat
As of the edition of 20 October 2026, Lidorestat is a small molecule: went quiet; acts on AKR1B1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
- Disease areas
- Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Lidorestat.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AKR1B1 | Aldo-keto reductase family 1 member B1 | P15121 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| The Institute for Diabetes Discovery | Lead sponsor of trials |